NDAORALCAPSULEPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIVDELZI (seladelpar lysine) is an oral small-molecule capsule approved by the FDA on August 14, 2024, as a novel therapeutic for primary biliary cholangitis (PBC). The drug's specific mechanism of action and indication details are not publicly disclosed in the available data, but it represents a new treatment option in the hepatology space. Seladelpar represents Gilead Sciences' entry into the rare liver disease market.
Growth8.6 years to LOE
Recently approved product in growth phase with Gilead's commercial backing, likely to expand team hiring in sales, marketing, and medical affairs roles over the next 2-3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LIVDELZI represents a rare disease growth opportunity with Gilead's resources and market entry position creating immediate hiring demand in sales, marketing, and medical affairs. Career professionals joining this product team will benefit from first-mover advantage, extended patent protection, and a focused rare-disease patient population requiring specialized engagement strategies.
Brand Manager
Worked on LIVDELZI at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.